| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 154, Issue 11 5637-5648, Copyright © 1995 by American Association of Immunologists
ARTICLES |
TF Gajewski, JC Renauld, A Van Pel and T Boon
Ludwig Institute for Cancer Research, Brussels Branch, Belgium.
The requirements for generating CD8+ CTLs against the mastocytoma P815 were first defined by using an allogeneic mixed lymphocyte tumor culture (MLTC). Both the expansion of effector lymphocytes and the acquisition of lytic activity were dependent on the presence of accessory cells, but not CD4+ lymphocytes. Several factors were examined for their ability to replace accessory cell function. Expression of B7-1 by P815 was sufficient to induce IL-2 production by CD8+ cells, but substantial proliferation was achieved only if IL-6 was provided as well. Although IL-12 had little effect on the net proliferation of developing effector cells, it increased specific lytic activity 10-fold, acted synergistically with B7-1 in induction of IFN- gamma production during primary stimulation, and resulted in a shift toward a Th1 cytokine profile following secondary stimulation. These costimulatory factors were then studied in a primary syngeneic MLTC by using splenocytes from nonimmunized DBA/2 mice, an approach that had never before succeeded in generating specific CTLs. The combination of B7-1, IL-6, and IL-12 was sufficient to induce P815-specific CTL activity after a 5-day MLTC, which was expanded optimally following secondary stimulation in the presence of B7-1, IL-2, and IL-7. The irrelevant syngeneic tumor L1210, constructed to express B7-1 and the P815-derived tumor Ag gene P1A, also generated CTLs that lysed the parental P815. The combination of B7-1, IL-6, and IL-12 should be useful in the derivation of other tumor-specific CTLs in vitro, and may constitute the optimal stimuli for rapid proliferation and differentiation of helper-independent, tumor-specific CTLs in vivo.
This article has been cited by other articles:
|
|
 |
|
  P. A. Cohen, G. K. Koski, B. J. Czerniecki, K. D. Bunting, X.-Y. Fu, Z. Wang, W.-J. Zhang, C. S. Carter, M. Awad, C. A. Distel, et al. STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells Blood, September 1, 2008; 112(5): 1832 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. I. Naslund, C. Uyttenhove, E. K. L. Nordstrom, D. Colau, G. Warnier, M. Jondal, B. J. Van den Eynde, and P. Liljestrom Comparative Prime-Boost Vaccinations Using Semliki Forest Virus, Adenovirus, and ALVAC Vectors Demonstrate Differences in the Generation of a Protective Central Memory CTL Response against the P815 Tumor J. Immunol., June 1, 2007; 178(11): 6761 - 6769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Teague, R. M. Tempero, S. Thomas, K. Murali-Krishna, and B. H. Nelson Proliferation and Differentiation of CD8+ T Cells in the Absence of IL-2/15 Receptor {beta}-Chain Expression or STAT5 Activation J. Immunol., September 1, 2004; 173(5): 3131 - 3139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Peterson, H. Harlin, and T. F. Gajewski Immunization With Melan-A Peptide-Pulsed Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 Induces Clinical Activity and T-Cell Responses in Advanced Melanoma J. Clin. Oncol., June 15, 2003; 21(12): 2342 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhai, L. Meng, F. Gao, R. W. Busuttil, and J. W. Kupiec-Weglinski Allograft Rejection by Primed/Memory CD8+ T Cells Is CD154 Blockade Resistant: Therapeutic Implications for Sensitized Transplant Recipients J. Immunol., October 15, 2002; 169(8): 4667 - 4673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bilsborough, C. Uyttenhove, D. Colau, P. Bousso, C. Libert, B. Weynand, T. Boon, and B. J. Van den Eynde TNF-Mediated Toxicity After Massive Induction of Specific CD8+ T Cells Following Immunization of Mice with a Tumor-Specific Peptide J. Immunol., September 15, 2002; 169(6): 3053 - 3060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Deng, E. Goluszko, E. Tuzun, H. Yang, and P. Christadoss Resistance to Experimental Autoimmune Myasthenia Gravis in IL-6-Deficient Mice Is Associated with Reduced Germinal Center Formation and C3 Production J. Immunol., July 15, 2002; 169(2): 1077 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Belladonna, J.-C. Renauld, R. Bianchi, C. Vacca, F. Fallarino, C. Orabona, M. C. Fioretti, U. Grohmann, and P. Puccetti IL-23 and IL-12 Have Overlapping, but Distinct, Effects on Murine Dendritic Cells J. Immunol., June 1, 2002; 168(11): 5448 - 5454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mann, F. Oakley, P. W. M. Johnson, and D. A. Mann CD40 Induces Interleukin-6 Gene Transcription in Dendritic Cells. REGULATION BY TRAF2, AP-1, NF-kappa B, AND CBF1 J. Biol. Chem., May 3, 2002; 277(19): 17125 - 17138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. V. Serbina, V. Lazarevic, and J. L. Flynn CD4+ T Cells Are Required for the Development of Cytotoxic CD8+ T Cells During Mycobacterium tuberculosis Infection J. Immunol., December 15, 2001; 167(12): 6991 - 7000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Stober, R. Schirmbeck, and J. Reimann IL-12/IL-18-Dependent IFN-{{gamma}} Release by Murine Dendritic Cells J. Immunol., July 15, 2001; 167(2): 957 - 965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Kieper, M. Prlic, C. S. Schmidt, M. F. Mescher, and S. C. Jameson IL-12 Enhances CD8 T Cell Homeostatic Expansion J. Immunol., May 1, 2001; 166(9): 5515 - 5521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Makrigiannis, B. L. Musgrave, S. M. M. Haeryfar, and D. W. Hoskin Interleukin-12 can replace CD28-dependent T-cell costimulation during nonspecific cytotoxic T lymphocyte induction by anti-CD3 antibody J. Leukoc. Biol., January 1, 2001; 69(1): 113 - 122. [Abstract] [Full Text]
|
|
|
|
|
|
L. Peng, J. Kjaergaard, G. E. Plautz, D. E. Weng, S. Shu, and P. A. Cohen Helper-Independent, L-Selectinlow CD8+ T Cells with Broad Anti-Tumor Efficacy Are Naturally Sensitized During Tumor Progression J. Immunol., November 15, 2000; 165(10): 5738 - 5749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Haicheur, E. Bismuth, S. Bosset, O. Adotevi, G. Warnier, V. Lacabanne, A. Regnault, C. Desaymard, S. Amigorena, P. Ricciardi-Castagnoli, et al. The B Subunit of Shiga Toxin Fused to a Tumor Antigen Elicits CTL and Targets Dendritic Cells to Allow MHC Class I-Restricted Presentation of Peptides Derived from Exogenous Antigens J. Immunol., September 15, 2000; 165(6): 3301 - 3308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. K. Teague, B. C. Schaefer, D. Hildeman, J. Bender, T. Mitchell, J. W. Kappler, and P. Marrack Activation-induced Inhibition of Interleukin 6-mediated T Cell Survival and Signal Transducer and Activator of Transcription 1 Signaling J. Exp. Med., March 13, 2000; 191(6): 915 - 926. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Osterroth, A. Garbe, P. Fisch, and H. Veelken Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells Blood, February 15, 2000; 95(4): 1342 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Fallarino and T. F. Gajewski Cutting Edge: Differentiation of Antitumor CTL In Vivo Requires Host Expression of Stat1 J. Immunol., October 15, 1999; 163(8): 4109 - 4113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schirmbeck, K. Melber, and J. Reimann Adjuvants that enhance priming of cytotoxic T cells to a Kb-restricted epitope processed from exogenous but not endogenous hepatitis B surface antigen Int. Immunol., July 1, 1999; 11(7): 1093 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Hauser, F. Zipprich, I. Leblond, S. Wirth, and A. W. Hugin Protective Immunity from Naive CD8+ T Cells Activated In Vitro with MHC Class I Binding Immunogenic Peptides and IL-2 in the Absence of Specialized APCs J. Immunol., July 1, 1999; 163(1): 330 - 336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Chikamatsu, K. Nakano, W. J. Storkus, E. Appella, M. T. Lotze, T. L. Whiteside, and A. B. DeLeo Generation of Anti-p53 Cytotoxic T Lymphocytes from Human Peripheral Blood Using Autologous Dendritic Cells Clin. Cancer Res., June 1, 1999; 5(6): 1281 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bilsborough, A. Van Pel, C. Uyttenhove, T. Boon, and B. J. Van den Eynde Identification of a Second Major Tumor-Specific Antigen Recognized by CTLs on Mouse Mastocytoma P815 J. Immunol., March 15, 1999; 162(6): 3534 - 3540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Samoilova, J. L. Horton, B. Hilliard, T.-S. T. Liu, and Y. Chen IL-6-Deficient Mice Are Resistant to Experimental Autoimmune Encephalomyelitis: Roles of IL-6 in the Activation and Differentiation of Autoreactive T Cells J. Immunol., December 15, 1998; 161(12): 6480 - 6486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. McFarland, P. A. Harding, S. MaWhinney, R. T. Schooley, and D. R. Kuritzkes In Vitro Effects of IL-12 on HIV-1-Specific CTL Lines from HIV-1-Infected Children J. Immunol., July 1, 1998; 161(1): 513 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gueguen, J.-J. Patard, B. Gaugler, F. Brasseur, J.-C. Renauld, P. J. Van Cangh, T. Boon, and B. J. Van den Eynde An Antigen Recognized by Autologous CTLs on a Human Bladder Carcinoma J. Immunol., June 15, 1998; 160(12): 6188 - 6194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Dorfman, J. L. Schultze, A. Shahsafaei, S. Michalak, J. G. Gribben, G. J. Freeman, G. S. Pinkus, and L. M. Nadler In Vivo Expression of B7-1 and B7-2 By Follicular Lymphoma Cells Can Prevent Induction of T-Cell Anergy But Is Insufficient to Induce Significant T-Cell Proliferation Blood, December 1, 1997; 90(11): 4297 - 4306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Putzer, M. Hitt, W. J. Muller, P. Emtage, J. Gauldie, and F. L. Graham Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression PNAS, September 30, 1997; 94(20): 10889 - 10894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sciammas, P. Kodukula, Q. Tang, R.L. Hendricks, and J.A. Bluestone T Cell Receptor-gamma /delta Cells Protect Mice from Herpes Simplex Virus Type 1-induced Lethal Encephalitis J. Exp. Med., June 2, 1997; 185(11): 1969 - 1975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, R. H. Wenger, M. Zhao, and P. J. Nielsen Distinct Costimulatory Molecules Are Required for the Induction of Effector and Memory Cytotoxic T Lymphocytes J. Exp. Med., January 20, 1997; 185(2): 251 - 262. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
